The bill establishes a federal Sickle Cell Data Collection program administered by the Centers for Disease Control and Prevention that awards grants to States to build surveillance on incidence, prevalence, demographics, and healthcare use among people living with sickle cell disease. It also requires collaboration with existing grantees and the CDC to increase methodological standardization across surveillance activities.
Separately, the measure requires HHS to reinstate certain employees of the CDC’s Division of Blood Disorders and Public Health Genomics who were removed during large personnel actions beginning January 1, 2025. The act includes a five‑year, $10 million per-year authorization to fund the surveillance effort but leaves key operational details—data elements, privacy protections, grant selection criteria—to HHS rulemaking and grant guidance.
At a Glance
What It Does
Directs the HHS Secretary, through the CDC Director, to run a Sickle Cell Data Collection program that awards State grants to compile incidence, prevalence, demographic, and health‑care utilization data and to coordinate with prior program participants to standardize surveillance methods. It also mandates reinstatement of certain CDC Division employees removed in mass reductions beginning January 1, 2025.
Who It Affects
State health departments that apply for and receive grants, the CDC and HHS as program administrators, researchers and health planners who rely on surveillance data, and employees of the CDC Division of Blood Disorders and Public Health Genomics covered by the reinstatement rule.
Why It Matters
Fills a recognized gap in national sickle cell surveillance by channeling federal funds into state-level registries and data linkages and by pushing for standardized methods — both of which can reshape resource allocation, research, and care planning for a historically undercounted population.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill sets up a federal program — labeled the Sickle Cell Data Collection program — to be carried out by the CDC. The agency will award grants to States to build and maintain data systems that capture how many people have sickle cell disease, where they live, their demographic profiles, and how they use healthcare services.
The objective is not only to count cases but to generate actionable surveillance products that inform care delivery and policy for people living with sickle cell disease.
Grantees are required to collaborate with entities that previously received Sickle Cell Data Collection grants and with the CDC itself to increase standardization of surveillance methods. That language makes standardizing case definitions, data linkages, and analytic approaches a statutory aim, but the bill does not list the specific data elements, technical standards, or privacy safeguards; those details will be determined by CDC grant terms and guidance.Congress authorizes funding to support the program—$10 million per fiscal year for five years—creating a limited multi‑year window for states to build capacity.
The statute does not create a permanent entitlement or specify matching requirements, leaving open whether states must contribute funds or in‑kind resources. How CDC sequences awards, the reporting cadence it will require, and whether grants will prioritize existing registries or seed new ones are left to the agency’s implementation plan.The bill also addresses personnel: it orders the Secretary to reinstate ‘‘covered employees’’ from the CDC’s Division of Blood Disorders and Public Health Genomics who were removed on or after January 1, 2025 as part of workforce reductions meeting the statutory threshold.
The reinstatement requirement includes a narrow definition tied to the size and timing of the personnel action, which creates a targeted remedy for those displaced by specific reduction events rather than a broad rehiring mandate.
The Five Things You Need to Know
The statute requires the Secretary to carry out the program through the CDC Director (an agency‑level implementation pathway).
Grants are targeted to States (the bill uses the statutory term “States” as the eligible grantee category).
Congress authorizes $10,000,000 per year to run the program for fiscal years 2027 through 2031 (five annual appropriations).
The bill mandates active collaboration with recipients of the prior CDC Sickle Cell Data Collection grants to increase standardization of surveillance methods across jurisdictions.
The reinstatement provision covers CDC Division employees removed on or after January 1, 2025 when an agency action removed 3% or more of that Division’s workforce within a 60‑day period.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act’s name: the 'Candis King Hope for Sickle Cell Families Act.' This is purely nominal but signals the bill’s focus for codification and for administrative reference within HHS and CDC materials.
Establish Sickle Cell Data Collection program and grant authority
Directs the HHS Secretary, acting through the CDC Director, to carry out a program that collects data on sickle cell disease in the United States by awarding grants to States. Practically, that places the program within CDC grant authorities and requires the agency to design funding announcements, eligible activities, and reporting requirements. The statutory aim emphasizes incidence, prevalence, demographics, and healthcare utilization, which implies support for registries, claims linkage, hospital data, and analyses of service use patterns.
Standardization requirement with prior grantees
Requires grantees to collaborate with entities that received CDC Sickle Cell Data Collection grants before this law and with CDC to increase standardization. For implementers, that compels alignment on case definitions, data formats, and analytic methods where feasible, and signals that CDC grant guidance should favor interoperable systems rather than bespoke, incompatible registries.
Authorization of appropriations
Authorizes $10 million annually for fiscal years 2027–2031 to carry out the program. This is an authorization, not an appropriation; actual funding will depend on annual appropriations acts. The five‑year authorization creates a finite planning horizon for grantees and CDC and may shape grant terms, deliverables, and expectations about sustainability after FY2031.
Reinstatement of certain Division employees; definition
Directs HHS to reinstate 'covered employees' from the CDC’s Division of Blood Disorders and Public Health Genomics who were removed on or after January 1, 2025 in any agency action that removed 3% or more of that Division’s employees within a 60‑day period. The definition ties eligibility to a narrow class of workforce reductions and creates a statutory obligation for HHS to restore those positions, which carries personnel, budgetary, and administrative implications.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with sickle cell disease and their families — better surveillance should produce more accurate counts, clearer demographic patterns, and evidence on healthcare utilization that can inform care access, resource allocation, and targeted interventions.
- State health departments that receive grants — the bill provides federal dollars and an explicit mandate to build registries and data systems, potentially upgrading state surveillance capacity and technical infrastructure.
- Researchers and public health planners — standardized, multi‑state data will expand opportunities for population‑level studies, program evaluation, and more precise burden estimates.
- Minority health and advocacy organizations — improved data on a disease that disproportionately affects Black and Brown communities can strengthen advocacy, funding requests, and program design aimed at health equity.
Who Bears the Cost
- HHS and CDC — responsible for administering grants, developing guidance, monitoring compliance, and implementing the reinstatement requirement; these obligations consume agency staff time and budget.
- State health agencies — even with federal funding, States will need to allocate personnel, IT resources, and operational capacity to develop or expand registries, perform linkages, and meet reporting requirements.
- Healthcare providers and data holders — hospitals, labs, and payers may face new reporting requests or data‑sharing arrangements to populate surveillance systems, creating operational and compliance work.
- CDC Division of Blood Disorders — the reinstatement mandate may require reassigning positions, adjusting budgets, and reversing prior reorganizations, which can disrupt workload planning and internal priorities.
Key Issues
The Core Tension
The central dilemma is between the clear public‑health value of high‑quality, standardized surveillance for a historically underserved disease population and the practical limits and risks of creating linked, multi‑jurisdictional data systems: funding, privacy, state capacity, and the administrative cost of reversing prior personnel actions all pull in different directions with no single, risk‑free solution.
The bill sets programmatic goals but delegates nearly all implementing decisions to HHS/CDC: which data elements to collect, what privacy and security safeguards to require, how to award grants, and how to prioritize limited funds. That delegation allows the agency flexibility but creates uncertainty for States and stakeholders trying to plan for participation.
The authorization is modest ($10 million per year) relative to the multi‑jurisdictional, IT‑intensive work of building interoperable registries and performing claims or hospital data linkages, so States should expect tradeoffs between depth of surveillance and breadth of coverage.
The reinstatement provision is narrowly drawn, tied to personnel removals of a defined size and timing, and creates operational questions: which specific positions must be restored, how to integrate reinstated staff into current organizational structures, and how to reconcile reinstatement with collective‑bargaining or civil service rules. On the data side, the push for standardization raises privacy tradeoffs: more centralized, linkable datasets increase epidemiologic value but heighten re‑identification risk for a small, stigmatized population.
The statute does not prescribe de‑identification standards, data access controls, or penalties for misuse, leaving those significant policy choices to agency rulemaking.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.